## HOLX: Hologic, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG 1.66 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($74.29)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Hologic data highlights AIâ€™s role in improving mammography accuracy**
- Source: DOTmed | 20251218T150157 | Bullish | Relevance: 100%
- New data from Hologic's Genius AI Detection software, published in the American Journal of Roentgenology, demonstrates AI's potential in identifying breast cancers missed by initial mammography screenings. A retrospective review at Massachusetts General Hospital found that the AI flagged 32% of false-negative exams as suspicious, accurately localizing future cancer sites. This study reinforces the value of AI as a "second set of eyes" in breast cancer detection, though further research is needed to integrate it into clinical practice.

**2. Hologic (HOLX) insider reports 90 shares withheld for tax obligations**
- Source: Stock Titan | 20251217T220808 | Neutral | Relevance: 100%
- A Hologic executive, identified as President, GYN Surgical, reported a routine tax-related stock transaction. On December 12, 2025, 90 shares of Hologic common stock were disposed of at $75 per share, withheld to satisfy tax obligations from vested restricted stock units. Following this, the officer directly owns 17,512 Hologic shares.

**3. Study: AI-Powered Mammography Technology Helps Flag Breast Cancer Cases Initially Interpreted as Negative**
- Source: Imaging Technology News | 20251217T050831 | Bullish | Relevance: 99%
- A new study reveals that Hologic's AI-powered mammography solution can significantly improve the detection of breast cancers, particularly those initially missed. The Genius AI Detection technology flagged 32% of false-negative cases and accurately localized areas of suspicion in nearly 90% of previously identified cancers. This technology aims to assist radiologists in identifying potential cancers that might otherwise remain undetected, showcasing its promising role in enhancing breast cancer detection.

**4. Digital Breast Tomosynthesis Equipment Market Set to Boom |**
- Source: openPR.com | 20251219T070817 | Bullish | Relevance: 93%
- A new report by Coherent Market Insights forecasts significant growth for the Digital Breast Tomosynthesis Equipment Market from 2025 to 2032, driven by increasing industry demand and technological advancements. The study provides an overview of market size, revenue trends, and key growth factors, alongside detailed competitive analysis and strategic opportunities for stakeholders. It covers leading companies, segmentation by product type and end-user, and regional assessments, offering actionable insights for market decisions.

**5. Virtual Biopsy Market Emerging Player Outperforming | GE Healthcare, Hologic, Hitachi**
- Source: openPR.com | 20251217T110810 | Somewhat-Bullish | Relevance: 91%
- The global Virtual Biopsy Market is projected to grow substantially, reaching USD 3.16 billion by 2033 with a 14.6% growth rate, according to HTF Market Intelligence. This market leverages advanced imaging, AI, and machine learning for non-invasive disease detection and monitoring. Key drivers include the rising prevalence of chronic diseases and demand for safer diagnostic alternatives, while market opportunities lie in emerging markets and AI-based predictive tools.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 16 ($0.27M) |
| Sells | 25 ($6.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-2.2%)
- T. Rowe Price Invest: 9.7% (-10.5%)
- Blackrock Inc.: 8.7% (-2.7%)
- Manufacturers Life I: 4.7% (-5.2%)
- State Street Corpora: 4.5% (-1.2%)

### Key Risks

1. Insider selling cluster: $6.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.66 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (3.5x). Insider selling cluster ($6.6M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 8 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $16.7B |
| Beta | 0.70 |
| 52W Range | $51.90 - $75.34 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.66 |
| Forward P/E | 15.0 |
| Current P/E | 16.4 |
| YoY Growth | 9.6% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 0.9% to -0.2% (-1.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). Elevated volume (1.6x 20MA), institutional activity likely. OFD pattern: -SLH (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.24% (CS: 48) | Neutral |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | -0.12 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.019x | Above |
| vs SMA200 | 1.138x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $74.95
- **Stop Loss:** $74.29 (0.9% risk)
- **Target:** $75.61 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 1818
- **Position Value:** $136,259.10
- **Portfolio %:** 136.26%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-04 (Est: $1.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.10 | $1.13 | +2.7% |
| 2025Q2 | $1.05 | $1.08 | +2.7% |
| 2025Q1 | $1.02 | $1.03 | +1.4% |
| 2024Q4 | $1.02 | $1.03 | +1.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*